44ACTIVITIES
1ORGS REPRESENTED
60BILLS
Organizations represented
1Orgs whose LD-2 filings list David as an active lobbyist, sorted by activity volume.
Bills they file on
60S. 229625 mentions
S. 265824 mentions
S. 4314 mentions
S. 70814 mentions
S. 104014 mentions
S. 104114 mentions
S. 109514 mentions
S. 109614 mentions
S. 109714 mentions
H.R. 89014 mentions
H.R. 157414 mentions
S. 65214 mentions
S. 83214 mentions
S. 89114 mentions
S. 93214 mentions
+ 45 more bills referenced in their activities
Topics in Filings
80Policy topics David files on across all their LD-2 activities.
RESTORE Patent Rights Act×28
Supply chain policy×28
Big Savings Act×25
Biopharmaceutical innovation policy×25
BIOSECURE Act×24
Most Favored Nation×24
One Big Beautiful Bill Act×15
Skinny Labels×14
Affordable Prescriptions for Patients Act×14
Stop STALLING Act×14
Preserve Access to Affordable Generics and Biosimilars Act×14
Interagency Patent Coordination and Improvement Act×14
Show all 80 topics (+68 more) ▾
Bayh-Dole march-in rights policy×14
Patent thicket policy×14
AI patent policy×14
Patent eligibility policy×14
Post-grant proceeding policy×14
Patent submission policy×14
Modernizing and Ensuring PBM Accountability×14
Accountability, and Integrity Now and for the Future×14
Vaccine policy×14
Inflation Reduction Act×14
Pharmacy Benefit Manager reform×14
Drug cost and pricing policy×14
Drug importation policy×14
FDA policy×14
Orphan Drug Act×14
Compounding policy×14
Clinical trial policy×14
Issues 340B drug discount program policy×14
Biosimilar approval and reimbursement policy×14
Artificial intelligence policy×14
International intellectual property and market access policy×14
Pricing and reimbursement policy×14
WTO TRIPS waiver policy×14
China outbound investment policy×14
FDA Modernization×14
Medication Affordability and Patent Integrity Act×13
Biosimilar Red Tape Elimination Act×13
Stopping Pharmas Ripoffs and Drug Savings For All Act×12
Bipartisan Health Care Act×12
IRA price negotiation expansion policy×12
MAHA Commission Report×12
Make Our Children Healthy Again Competition policy×12
Issues 340B rebate pilot program Patient assistance program policy×12
Biosimilars Access and Affordability Act×12
Patent fee policy×11
PBM Price Transparency and Accountability Act×11
Mikaela Naylon Give Kids a Chance Act×11
PBM Reform×11
HELP Copays Act×11
Antimicrobial resistance policy×11
US-UK Framework Agreement×11
CLEAR LABELS Act×10
Most Favored Patients Act×10
FAIR ACT×10
SECURE Rx Act×10
User fee issues×4
Rural Development×4
Patent use codes policy×3
Give Kids a Chance Act×3
Antimicrobial resistance×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×2
Res. 566: Providing for consideration of the Senate amendment to the bill×2
Science, and Related Agencies Appropriations Act, 2026×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Tariff policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
Legislative Branch×1
Open Payments Expansion Act×1
Issue mix
LDA general-issue codes weighted by activity count.
Copyright/Patent/Trademark14
Health Issues14
Trade (domestic/foreign)14
Budget/Appropriations2